The Scan­gos lega­cy: A block­buster MS record with lin­ger­ing doubts about the pipeline

Six years ago, George Scan­gos was re­cruit­ed to head a turn­around team at what was billed as a trou­bled Bio­gen. And it wasn’t long be­fore a big ap­proval for a new mul­ti­ple scle­ro­sis block­buster trig­gered a round of ap­plause—and a bull­ish surge in the com­pa­ny’s stock price—that last­ed for years.

To­day, Scan­gos says his time is up at Bio­gen, well af­ter the ap­plause pe­tered out last year and the mar­ket be­gan to grow rest­less over the CEO’s less suc­cess­ful sec­ond act in a bear­ish mar­ket. In the next few months, he’ll step aside, once his suc­ces­sor can be found to helm the in­flu­en­tial Big Biotech, an in­sti­tu­tion­al land­mark in­side the Boston/Cam­bridge hub.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.